Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

NCT03816345 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03816345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03816345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
July 16, 2019
Completion date
March 30, 2028
Enrollment
300 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune disease, crohn disease, dermatomyositis, hematopoietic and lymphoid cell neoplasm, inflammatory bowel disease, malignant solid neoplasm, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, sjogren syndrome, systemic lupus erythematosus, systemic scleroderma, ulcerative colitis